Siemens Healthineers Hit by Triple Threat as Shares Plunge to Multi-Year Lows

Siemens Healthineers hits 52-week low as German hospital reforms, tariffs, and a looming Siemens stake reduction threaten profits and financial stability.

The stars have aligned against Siemens Healthineers in spectacular fashion. Germany’s medical technology heavyweight has seen its stock hammered by a toxic cocktail of domestic austerity, global trade friction, and a looming structural overhaul that threatens to strip away a critical financial safety net. On Thursday, the shares touched a fresh 52-week trough of €33.62, extending a year-to-date decline of roughly 24% that has wiped billions from the company’s market value.

The latest blow came from Berlin, where the federal cabinet approved a sweeping healthcare reform package designed to plug the widening deficit in Germany’s statutory health insurance system. By 2027, the government aims to save around €20 billion, with more than 40% of those cuts—some €8 billion—falling directly on the hospital sector. For Siemens Healthineers, whose core business revolves around selling expensive imaging systems and laboratory diagnostics to cash-strapped clinics, the implications are stark. Hospitals are already postponing capital expenditure decisions, and the reform will only deepen their reluctance to invest.

That political headwind compounds an already punishing operating environment. The company is grappling with tariff-related costs of approximately €400 million for the current fiscal year, while adverse currency movements are expected to eat up an additional €250 million. In Asia, a government anti-corruption campaign in China has weighed on first-quarter revenues in the diagnostics division, forcing the company to lean on its full-year guidance. Management still expects adjusted earnings per share to land between €2.20 and €2.40, but the path to that target looks increasingly narrow.

The stock’s technical picture offers little comfort. After sliding to a five-year low of €33.80 on Wednesday, the shares staged a modest bounce to €34.09 on Thursday—a gain that analysts describe as tentative at best. The relative strength index has dipped to around 28, a level that typically signals an oversold condition, but the broader downtrend remains firmly intact. The stock now trades nearly 22% below its 200-day moving average, a key gauge of long-term momentum, and any recovery attempt lacks conviction. The sector-wide alarm was sounded by US rival GE HealthCare, which recently slashed its profit forecast—a move that market observers interpret as a red flag for the entire medtech space.

Adding to the pressure, the parent company Siemens AG is moving ahead with plans to reduce its grip on the subsidiary. Under a proposal set for a shareholder vote at the annual meeting in February 2027, Siemens intends to transfer roughly 30% of its Healthineers stake directly to its own shareholders. That would cut its current majority holding from 67% to around 37%, dramatically loosening the corporate umbilical cord. But the spin-off carries a hidden cost: once the transaction is complete, Siemens will no longer guarantee up to €13.9 billion in loans for Healthineers, forcing the medical technology firm to refinance that massive debt burden on its own. The shift in capital structure is a fundamental change that investors are only beginning to price in.

All eyes now turn to May 7, when Siemens Healthineers will report its second-quarter results. The earnings release, scheduled for 7:30 a.m. local time, will be the first real test of whether management can convince the market that its annual targets remain achievable despite the gathering storm. Investors will scrutinize margins in the imaging segment, which accounts for the bulk of group profits, and look for signs of stabilization in the Chinese diagnostics business. If the numbers disappoint, the recent lows may prove to be merely a way station on a longer descent.